The objectives of this EAG will include:

 

1. Advocacy for the importance of HCV vaccine development to all relevant international organisations (e.g. WHO, Gates Foundation, industry)

2. Identify ongoing funding sources for HCVax

3. Establish partnerships with key stakeholder organisations, including consumer organisations

4. Develop a business case / modelling / cost-effectiveness analysis for HCV vaccines.